The ABCB6 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the ABCB6 gene in the HT29 colorectal adenocarcinoma background. This heterogeneous knockout pool enables loss-of-function studies without single-cell cloning, providing a versatile model for investigating ABCB6-dependent functions in epithelial cancer cells.
HT29 is a human colorectal adenocarcinoma cell line from a 44-year-old female, harboring mutations in APC and TP53. It retains epithelial differentiation potential under defined conditions, such as enterocytic maturation after sodium butyrate treatment. This well-characterized line serves as a standard for intestinal epithelial biology and colorectal cancer research, making it an ideal host for exploring ABCB6 function in tumor cell metabolism and drug resistance.
ABCB6 encodes a mitochondrial outer membrane ATP-binding cassette transporter that exports coproporphyrinogen III for heme biosynthesis, maintaining mitochondrial porphyrin homeostasis. Its expression is activated by oxidative stress via NRF2, hypoxia via HIF1A, and heme-responsive transcription factors. Downstream, ABCB6 modulates mitochondrial heme content, ROS levels, and apoptotic responses. The transporter interacts with heme, porphyrins, ferrochelatase, and mitochondrial import machinery. Key pathway partners include coproporphyrinogen oxidase, protoporphyrinogen oxidase, ALA synthase, and porphobilinogen deaminase.
In HT29 cells, ABCB6 disruption can perturb heme metabolism and redox balance, potentially altering chemosensitivity due to its involvement in substrate efflux and drug resistance. This knockout model is particularly relevant for studying ABC transporter-mediated drug resistance in colorectal cancer, a major therapeutic challenge. Additionally, since ABCB6 mutations are linked to familial pseudotumoral gout, porphyria, and blood group Langereis, these cells aid in modeling porphyrin trafficking defects and mitochondrial dysfunction associated with these disorders.
These polyclonal cells are suitable for dissecting heme biosynthesis in colorectal cancer, assessing chemosensitivity modulation, and modeling porphyria-associated cellular defects. Typical assays include western blotting and RT-qPCR for ABCB6, heme quantification, mitochondrial porphyrin measurements, drug sensitivity profiling, ROS detection, and apoptosis flow cytometry. The batch-to-batch consistency of polyclonal pools supports robust genetic screens and functional complementation. For further details, please contact Ascent Research.
